← Back to Search

99mTc-GP for Breast Cancer

Phase 1
Waitlist Available
Led By Tejal Patel, M.D.
Research Sponsored by SeeCure LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 99mtc-gp injection through 30 days
Awards & highlights

Study Summary

The purpose of this study is to evaluate the biodistribution and dosimetry of single dose of 99mTc-glycopeptide (99mTc-GP, 20-25 mCi) in 3 different doses of GP (5, 10and 20 mg)in patients with breast cancer at pre-chemotherapy.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 99mtc-gp injection through 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 99mtc-gp injection through 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine the best dose of 99mTc-GP in imaging based upon safety data and tumor-to background (T/B) count density ratios.
Secondary outcome measures
To determine the optimal time to imaging after injection of 99mTc-GP based upon tumor to-background (T/B) count density ratios at various times.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 99mTc-GPExperimental Treatment1 Intervention
99mTc-GP with SPECT/CT imaging & whole body scan.

Find a Location

Who is running the clinical trial?

SeeCure LLCLead Sponsor
Tejal Patel, M.D.Principal InvestigatorBreast Medical Oncologist, Methodist Cancer Center, Houston, Texas

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
2010. "The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01159405.
All > Uti
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top